China Heparin Industry Report, 2012-2014
  • Dec./2012
  • Hard Copy
  • USD $2,000
  • Pages:73
  • Single User License
    (PDF Unprintable)       
  • USD $1,900
  • Code: ZYM038
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $3,000
  • Hard Copy + Single User License
  • USD $2,200
China, abundant in heparin raw materials, has become one of the world’s largest heparin API producers and exporters, owning to the quality of heparin API having won international recognition gradually. Due to the euro debt crisis, the global market suffered a deep recession. Coupled that the heparin export standard has lifted, China’s export volume of heparin API was no more than 105.2 tons in 2011, approximating 14.6 trillion units (measured by 140IU/mg), with the proportion of around 45.9% in the global demand during the same period.

Leading heparin API suppliers worldwide include Shenzhen Hepalink Pharmaceutical, Changzhou Qianhong Bio-Pharma, Yantai Dongcheng Biochemicals and Nanjing King-Friend Biochemical Pharmaceutical, which have ranked top 4 industrial players by export for several years in a row, with the combined export value making up more than 70% of China’s total export value of heparin. There is no distinct change in terms of the export pattern. However, the export prices of China’s top 10 heparin exporters witnessed a downward mobility in 2011-2012H1. Nevertheless, it was not the same case for Dongying Tiandong Pharmaceutical and Jiangsu Medicine Health Care Article Imp. & Exp. (Group), whose export prices increased by 3.8% and 2.1% year-on-year  respectively in Jan.-May, 2012, due to the improved quality of exported products as well as the low cardinal number of exported prices in the preceding year.

Export Volume and Export Value Change of China Top 10 Heparin and Heparinate Exporters, Jan.-May, 2012

Meanwhile, Chinese heparin API flagship enterprises including Shenzhen Hepalink Pharmaceutical, Changzhou Qianhong Bio-Pharma, Yantai Dongcheng Biochemicals, Hebei Changshan Biochemical Pharmaceutical and Nanjing King-Friend Biochemical Pharmaceutical are projected to expand their capacities and improve the heparin industry chains. Among these tycoons, the first four ones have made IPO, while Nanjing King-Friend Biochemical Pharmaceutical is also preparing for IPO by accepting tutoring. According to public information issued by related enterprises, the heparin API capacity of China will increase by more than 18 trillion units by 2014, with the total capacity expected to exceed 30 trillion units, making up over 70% of the global demand.

Although China is a large country with rich heparin API, the downstream production of general heparin preparation and low molecular weight heparin preparation is still at the initial stage. In the high-end low molecular weight heparin preparation market, especially, joint ventures and foreign brands including Sanofi-Aventis, Pfizer and GSK have eroded into the Chinese market. According to China Pharmaceutical Industry Association, imported low molecular weight heparin calcium accounted for more than 60% of the total procurement of such products of representative hospitals in 22 Chinese cities in 2011.

However, with the improvement of R&D and technological strength, the competitiveness of made-in-China low molecular weight heparin preparation market is increasingly enhancing. A case in point is Hebei Changshan Biochemical Pharmaceutical Co., Ltd, the capacity of low molecular weight heparin calcium injection of which soared from 4 million pcs to 10 million pcs in 2011, with the sales increased by 68.4% year-on-year to RMB86.93 million, compared to the sales of RMB117 million in 2012H1, a year-on-year rise of 237.6%.

1. Profile of Heparin Industry
1.1 Definition & Classification
1.2 Industry Chain

2. Operating Environment of Chinese Heparin Industry
2.1 Entry Barriers
2.1.1 Policies
2.1.2 Technical Requirements
2.1.3 Capital Barrier
2.2 Supply and Demand in Global Market
2.3 Competition in Global Market
2.4 Global Market Forecast

3. Development of Heparin API Industry in China
3.1 Market Status Quo
3.2 Market Supply and Demand
3.3 Competitive Landscape
3.4 Import & Export
3.4.1 Export
3.4.2 Import
3.5 Development Outlook & Forecast

4. Development of Heparin Preparation Industry in China
4.1 Market Size
4.2 Competition Pattern
4.3 Market Segments
4.3.1 Low Molecular Weight Heparin Preparation
4.3.2 General Heparin Preparation
4.4 Development Outlook & Forecast

5. Key Chinese Heparin Manufacturers
5.1 Shenzhen Hepalink Pharmaceutical Co., Ltd
5.1.1 Profile
5.1.2 Operation
5.1.3 Revenue Structure
5.1.4 Gross Margin
5.1.5 R&D and Investment
5.1.6 Clients and Suppliers
5.1.7 Prospects
5.2 Changzhou Qianhong Bio-Pharma Co., Ltd
5.2.1 Profile
5.2.2 Operation
5.2.3 Revenue Structure
5.2.4 Gross Margin
5.2.5 R&D and Investment
5.2.6 Clients and Suppliers
5.2.7 Heparin Business
5.2.8 Prospects
5.3 Yantai Dongcheng Biochemicals Co., Ltd
5.3.1 Profile
5.3.2 Operation
5.3.3 Revenue Structure
5.3.4 Gross Margin
5.3.5 R&D and Investment
5.3.6 Clients and Suppliers
5.3.7 Heparin Business
5.3.8 Prospects
5.4 Hebei Changshan Biochemical Pharmaceutical Co., Ltd
5.4.1 Profile
5.4.2 Operation
5.4.3 Revenue Structure
5.4.4 Gross Margin
5.4.5 R&D and Investment
5.4.6 Clients and Suppliers
5.4.7 Prospects
5.5 Tianjin Chase Sun Pharmaceutical Co., Ltd
5.5.1 Profile
5.5.2 Operation
5.5.3 Revenue Structure
5.5.4 Gross Margin
5.5.5 R&D and Investment
5.5.6 Clients and Suppliers
5.5.7 Heparin Business
5.5.8 Prospects
5.6 Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd
5.6.1 Profile
5.6.2 Operation and Prospects
5.7 Wanbang Biopharmaceuticals
5.7.1 Profile
5.7.2 Operation and Prospects
Application of Heparin Preparations
Heparin Industry Chain
Difference between Heparin Sodium API and Heparin Standardized Requirements
Heparin Preparation Market Scale and YoY Growth Worldwide, 2006-2011 
Performance: Low Molecular Weight Heparin Preparation vs. General Heparin Preparation 
Global Heparin Preparation Distribution by Products, 2006-2011
Global Heparin Preparation Distribution by Region, 2011
Heparin API Demand and YoY Growth Worldwide, 2007-2011
Sales of Enoxaparin Worldwide by Product, 2010-2012 
Regulatory Exclusivity of Lovenox, as of late 2011
Global Heparin Preparation Market Scale, 2011-2014E 
Global Heparin API Demand, 2011-2014E 
Gross Margin of Major Heparin API Manufacturers in China, 2008-2012 
Capacity of Crude Heparin in China, 2009-2011 
Average Export Price of Heparin and Heparinate, 2008-2012 
Capacity of Major Heparin API Manufacturers in China, as of June 2012 
Export Volume and Export Value of Heparin and Heparinate in China, 2008-2012
Export Price of Heparin and Heparinate in China, 2008-2012
Top 10 Export Destinations of Heparin and Heparinate in China by Value, 2011-2012 
Top 10 Heparin and Heparinate Enterprises in China by Export Value, 2011
Export Volume and Export Value of Heparin and Heparinate in China, Jan.-May, 2012 
Import Volume, Import Value and Unite Price of Heparin and Heparinate in China, 2008-2011
Planned / Ongoing Heparin Sodium API Projects in China, as of June 2012 
Heparin Preparation Market Scale and YoY Growth of China, 2007-2011 
Market Share of Heparin Preparation Products in China, 2011 
Main Manufacturers of Heparin Sodium Injection Solution and Heparin Calcium Injection Solution in China
Manufacturers of Low-molecular Heparin Sodium Preparations and Low-molecular Heparin Calcium Preparations
China Low Molecular Weight Heparin Preparation Market Scale, 2009-2011 
Purchase Value of Low Molecular Weight Heparin Calcium of Chinese Representative Hospitals, 2010-2011 
Low Molecular Weight Heparin Preparation Imported Value of Representative Hospitals in 22 Chinese Cities, 2010-2011 
Competition Pattern of China Low Molecular Weight Heparin Calcium Market, 2009 
Competition Pattern of China Low Molecular Weight Heparin Sodium Market, 2009
China Heparin Preparation Market Scale and YoY Growth, 2011-2014 
Assets and Net Income of Holding Subsidiaries under Hepalink, 2012H1 
Revenue and Profit of Hepalink, 2008-2012
Revenue of Hepalink by Product, 2008-2012
Revenue of Hepalink by Region, 2008-2012
Gross Margin of Hepalink by Product, 2008-2012
R&D Investment and Proportion in Revenue of Hepalink, 2009-2011
Revenue of Hepalink from the Top 5 Clients and Proportion, 2008-2012 
Revenue and Operating Income of Hepalink, 2011-2014E
Assets, Revenue and Net Income of Subsidiaries under Qianhong Bio-Pharma, 2012H1 
Revenue and Profit of Qianhong Bio-Pharma, 2008-2012
Revenue of Qianhong Bio-Pharma by Product, 2008-2012
Revenue of Qianhong Bio-Pharma by Region, 2008-2012
Gross Margin of Qianhong Bio-Pharma by Product, 2008-2012
R&D Investment and Proportion in Revenue of Qianhong Bio-Pharma, 2009-2011
Scheduling of Planned/Ongoing Projects of Qianhong Bio-Pharma, as of June 2012
Top 5 Clients, Revenue Contribution and Proportion of Qianhong Bio-Pharma, 2011 
Purchase Value of Qianhong Bio-Pharma’s Top 5 Suppliers and Revenue Contribution of Qianhong Bio-Pharma’s Top 5 Clients, 2009-2012 
Revenue and Gross Margin from Heparin Business of Qianhong Bio-Pharma, 2008-2012 
Revenue and Operating Income of Qianhong Bio-Pharma, 2011-2014 
Assets, Revenue and Net Income of Subsidiaries under Dongcheng Biochemicals, 2012H1 
Revenue and Profit of Dongcheng Biochemicals, 2008-2012
Revenue of Dongcheng Biochemicals by Product, 2008-2012
Revenue of Dongcheng Biochemicals by Region, 2008-2012
Gross Margin of Dongcheng Biochemicals by Product, 2008-2012
R&D Investment and Proportion in Revenue of Dongcheng Biochemicals, 2008-2012
Revenue and Gross Margin from Heparin Sodium API Business of Dongcheng Biochemicals, 2008-2012 
Heparin Sodium API Price of Dongcheng Biochemicals, 2009-2011
Revenue Contribution of Dongcheng Biochemicals’ Top 5 Heparin Sodium API Clients, 2009-2011
Scheduling of Heparin Sodium API Projects of Dongcheng Biochemicals, 2013-2015E
Revenue and Profit of Dongcheng Biochemicals, 2011-2014E
Revenue and Profit of Hebei Changshan Biochemical Pharmaceutical, 2008-2012
Revenue of Hebei Changshan Biochemical Pharmaceutical by Product, 2008-2012
Revenue of Hebei Changshan Biochemical Pharmaceutical by Region, 2008-2012
Gross Margin of Hebei Changshan Biochemical Pharmaceutical by Product, 2008-2012
R&D Investment and Proportion in Revenue of Hebei Changshan Biochemical Pharmaceutical, 2009-2011
Product Research Scheduling of Hebei Changshan Biochemical Pharmaceutical, as of late 2011
Name List, Revenue Contribution and Proportion of Top 5 Clients of Hebei Changshan Biochemical Pharmaceutical, 2011
Heparin Product Certificates Won by Hebei Changshan Biochemical Pharmaceutical Overseas, as of late 2011
Revenue and Profit of Hebei Changshan Biochemical Pharmaceutical, 2011-2014E
Revenue and Profit of Tianjin Chase Sun Pharmaceutical, 2008-2012
Revenue of Tianjin Chase Sun Pharmaceutical by Product, 2008-2012
Revenue of Tianjin Chase Sun Pharmaceutical by Region, 2008-2012 
Gross Margin of Tianjin Chase Sun Pharmaceutical by Product, 2008-2012
R&D Investment and Proportion in Revenue of Tianjin Chase Sun Pharmaceutical, 2009-2011
Name List, Revenue Contribution and Proportion of Top 5 Clients of Tianjin Chase Sun Pharmaceutical, 2011
Name List, Purchase Value and Proportion of Top 5 Suppliers of Tianjin Chase Sun Pharmaceutical, 2011
Revenue and Gross Margin from Heparin Business of Tianjin Chase Sun Pharmaceutical, 2008-2012
Revenue and Operating Income of Tianjin Chase Sun Pharmaceutical, 2011-2014
Assets and Net Income of Wanbang Biopharmaceuticals, 2008-2011

China Vacuum Blood Collection Industry Report, 2014-2017

The vacuum blood collection system consisting of vacuum blood collection tubes, disposable blood collection needles, tourniquets, etc transfers human venous blood to closed containers and makes it int...

China Pharmaceutical Excipients Industry Report, 2014-2017

Pharmaceutical excipients refer to adjuvants and additives used for production of pharmaceuticals and compounding of prescriptions. In addition to active ingredients, pharmaceutical excipients are als...

China Recombinant Protein Drug Industry Report, 2014-2017

The Chinese recombinant protein drug market has been expanding rapidly owing to the improvement of demand rigidity, consumption ability and the like. During 2005-2013, sales of recombinant protein dru...

China Heparin Industry Report, 2014-2017

As the world's major heparin API producer and exporter, China boasts enormous raw materials, which provides a strong support for the production of China’s heparin products. In 2013, the live pigs rais...

Global and China Monoclonal Antibody Industry Report, 2014-2019

Despite world-wide economic downturn and great changes in exchange rate, benefiting from robust market demand, global monoclonal antibody market size exceeded USD 80 billion in 2013, still one of biot...

Global and China DNA Sequencing Industry Research Report, 2014-2017

DNA sequencing is the process of reading nucleotide bases in a specific DNA molecule, that is to say determining the arrangement mode of adenine, thymine, cytosine, and guanine. It can be applied in a...

Global and China Stem Cell Industry Report, 2014-2017

Stem cells are undifferentiated biological cells that can differentiate into specialized cells and can divide (through mitosis) to produce more stem cells. Stem cell therapy can be applied to treatmen...

China Human Vaccine Industry Report, 2014-2017

Vaccines can prevent and control infectious diseases, so the demand for these biological products is relatively rigid. In 2013, China’s human vaccine lot release volume grew by 4.9% from a year earlie...

China Blood Product Industry Report, 2014-2017

Plasma resource reserves and control are crucial to the development of blood products industry. Although the closure of 16 plasma collection stations in Guizhou in 2011 didn’t cause major disruption t...

China Animal Vaccine Industry Report, 2013-2016

Animal vaccine is a kind of biological agent that enables inoculated animals to produce active immunity for disease prevention. Europe and the United States and other developed countries are the main ...

China Contract Research Organization (CRO) Industry Report, 2013-2016

China CRO industry has developed rapidly in recent years, registering a CAGR of 27.2% during 2007-2013, of which the market size reached RMB 36 billion in 2013, occupying 10% of global market share. ...

Global and China Biodegradable Plastics Industry Report, 2013-2016

Global biodegradable plastic production and demand have grown rapidly in recent years, and the capacity reached 1-1.5 million t/a in 2012-2013. Among dozens of biodegradable plastic varieties develope...

Global and China Industrial Enzyme Industry Report, 2014-2016

In 2007-2013, the global industrial enzyme market size grew at the CAGR of 5.7%, reaching USD4.04 billion in 2013, 1.4 times that in 2007. The global industrial enzyme market is monopolized by a small...

China Heparin Industry Report, 2013-2015

Since the small intestines of pigs (raw materials for production of heparin) in China are abundant (the pig slaughtering volume in China approximates 50% of globe’s total) and heparin APIs are gradual...

China Lactic Acid and Derivative Industry Report, 2013

China’s lactic acid capacity and output continued to grow at the respective CAGR of 22.7% and 28.7% in 2007-2011. But limited by market demand, the annual output of most vendors was below their design...

China Human Vaccine Industry Report, 2012-2015

In the wake of China's economic growth and enhanced disease prevention awareness, Chinese human vaccine market has been expanding. In 2012, Chinese human vaccine market valued RMB10.5 billion with the...

China Blood Product Industry Report, 2012-2015

Plasma is a key raw material of the blood product industry. In August 2011, China shut down 16 plasma stations in Guizhou, resulting in a decrease of 15% in the plasma volume of the year. However, due...

China Animal Vaccine Industry Report, 2012-2015

In view of the frequent occurrence of animal epidemic diseases over the years, the Chinese government has increased investment in epidemic prevention and implemented compulsory immunization system. Be...

2005-2014 All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号